Literature DB >> 6185197

VAB-6 combination chemotherapy without maintenance in treatment of disseminated cancer of the testis.

D Vugrin, W F Whitmore, R B Golbey.   

Abstract

Thirty-six men with Stage III or bulky Stage II malignant germ cell tumors of the testis who received no prior chemotherapy were treated with the VAB-6 protocol without maintenance and 34 were evaluable. The VAB-6 regimen is a 3-4 month program beginning with successive inductions at 3-4 week intervals: day 1, cyclophosphamide 600 mg/m2 of body surface, bleomycin 30 mg, vinblastine 4 mg/m2 and dactinomycin 1 mg/m2 intravenously; days 1-3, bleomycin 20 mg/m2/day X 3 by continuous 24-hour intravenous infusion; and day 4, cis-platinum 120 mg/m2 intravenously. Complete responders receive a fourth induction and are followed thereafter without further chemotherapy. Incomplete responders have resection of residual disease one month after the third induction. If the resected specimen contains malignant tissue, an additional two inductions are given. Thirty-one of 34 (91%) evaluable patients achieved complete remission and 28 remain in complete remission with median follow up of 24+ months. Chemotherapy alone was most effective in patients with minimal metastatic disease, with no teratoma in primary tumor, and with pure seminoma. Patients with advanced metastatic deposits or with teratoma in the primary tumor frequently required combined chemotherapy and surgery to achieve disease free status. Myelosuppression was the principal potentially serious toxicity. With effective induction, maintenance chemotherapy is not necessary.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6185197     DOI: 10.1002/1097-0142(19830115)51:2<211::aid-cncr2820510207>3.0.co;2-#

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Chemotherapy for non-seminomatous germ-cell tumours.

Authors:  P M Wilkinson
Journal:  J R Soc Med       Date:  1985       Impact factor: 5.344

2.  Testicular germ cell tumours--a model for a new approach to treatment of adult solid tumours.

Authors:  R T Oliver
Journal:  Postgrad Med J       Date:  1985-02       Impact factor: 2.401

3.  Rare cancers and specialist centres.

Authors:  R T Oliver
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-08

4.  Combination salvage chemotherapy using cisplatin and teniposide for patients with refractory germinal testicular tumors.

Authors:  T Kotake; T Miki
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Noncancerous pulmonary lesions in patients with metastatic testicular germ cell cancer.

Authors:  K Suzuki; H Nakazato; Y Ono; Y Takezawa; K Kurokawa; T Suzuki; I Yoshida; K Suzuki; H Yamanaka
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

6.  Significance of presence of teratomatous elements in the primary tumour of testicular cancer.

Authors:  K Suzuki; H Nakazato; K Matsumoto; K Kurokawa; T Suzuki; K Suzuki; H Yamanaka
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.